Esophageal Cancer, Gastric Cancer
Conditions
Keywords
Circulating Tumor DNA
Brief summary
This is a prospective cohort study designed to evaluate the treatment effect as well as predictive and prognostic factors with special emphasis on the clinical utility of ctDNA in plasma in patients with gastroesophageal cancer. Patients with gastroesophageal cancer are included in 5 separate cohorts scheduled for * Surgical resection + perioperative chemotherapy (cohort 1) * Neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2) * Definitive chemoradiotherapy with curative intent (cohort 3) * Systemic therapy with the intent to prolong survival (cohort 4) * Palliative treatment without the use of chemotherapy (cohort 5)
Interventions
DIAGNOSTIC_TESTCirculating tumor DNA
Measurement of circulating tumor DNA from plasma over a period of 2 years.
Sponsors
Rigshospitalet, Denmark
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Gastroesophageal cancer Age 18 years or older Able to understand and sign written informed consent
Exclusion criteria
Patients not providing informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to recurrence | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression | 1 year |
| Overall survival | 5 year |
| Response rate RECIST 1.1 | through study completion, an average of 1 year |
| Response duration RECIST 1.1 | through study completion, an average of 1 year |
Countries
Denmark
Contacts
Primary ContactMorten Mau-Sørensen, MD, PhD
Outcome results
None listed